Gossamer Bio, Inc. — Director's Dealing 2019

Feb 12, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Gossamer Bio, Inc. (GOSS)
CIK: 0001728117
Period of Report: 2019-02-12

Reporting Person: Christian Waage (EVP & General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-12	Common Stock	C	3454	—	Acquired	3454	Indirect
2019-02-12	Common Stock	P	1550	$16.00	Acquired	501498	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-12	Series B Preferred Stock	$	C	15543	Disposed		Common Stock (3454)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	22222	Indirect

Footnotes

F1: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.

F2: Includes 369,871 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreement between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on November 18, 2021, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. The shares are also subject to certain accelerated vesting provisions as set forth in more detail in the employment agreement between the Issuer and the Reporting Person.